Clinical Trials Logo

Clinical Trial Summary

The goal of this expanded access program is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory acute myeloid leukemia (AML).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05627466
Study type Expanded Access
Source Gilead Sciences
Contact
Status No longer available
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT05731219 - UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05061147 - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Phase 1/Phase 2
Not yet recruiting NCT05548088 - LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT03504410 - Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML Phase 3
Enrolling by invitation NCT05332054 - Long-Term Follow-up Study
Withdrawn NCT03904069 - Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML Phase 1
Completed NCT05518357 - LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03190278 - Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Completed NCT02665143 - A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Phase 2
Completed NCT03886831 - A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Phase 1
Recruiting NCT05722171 - Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Early Phase 1
Completed NCT03318016 - Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT06084819 - Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 2